Thomas Bohn outlines how the life sciences industry in Western Switzerland has continued to perform well despite the COVID-19 pandemic, highlights some of the key recent investments in the Greater Geneva Bern area (GGBa), and gives an overview of what the region has to offer global companies across the life sciences value chain.
Despite the COVID-19 pandemic, this year’s results have been even better than last year’s; a testament to Switzerland’s resilience and its strong appeal as a safe haven for investment in times of crisis
